BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 29134945)

  • 1. Drug-drug interaction potential of the HBV and HDV entry inhibitor myrcludex B assessed in vitro.
    Blank A; Meier K; Urban S; Haefeli WE; Weiss J
    Antivir Ther; 2018; 23(3):267-275. PubMed ID: 29134945
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reduced hepatitis B and D viral entry using clinically applied drugs as novel inhibitors of the bile acid transporter NTCP.
    Donkers JM; Zehnder B; van Westen GJP; Kwakkenbos MJ; IJzerman AP; Oude Elferink RPJ; Beuers U; Urban S; van de Graaf SFJ
    Sci Rep; 2017 Nov; 7(1):15307. PubMed ID: 29127322
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical effects of NTCP-inhibitor myrcludex B.
    Cheng D; Han B; Zhang W; Wu W
    J Viral Hepat; 2021 Jun; 28(6):852-858. PubMed ID: 33599010
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Humanized chimeric uPA mouse model for the study of hepatitis B and D virus interactions and preclinical drug evaluation.
    Lütgehetmann M; Mancke LV; Volz T; Helbig M; Allweiss L; Bornscheuer T; Pollok JM; Lohse AW; Petersen J; Urban S; Dandri M
    Hepatology; 2012 Mar; 55(3):685-94. PubMed ID: 22031488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of chronic hepatitis D with the entry inhibitor myrcludex B: First results of a phase Ib/IIa study.
    Bogomolov P; Alexandrov A; Voronkova N; Macievich M; Kokina K; Petrachenkova M; Lehr T; Lempp FA; Wedemeyer H; Haag M; Schwab M; Haefeli WE; Blank A; Urban S
    J Hepatol; 2016 Sep; 65(3):490-8. PubMed ID: 27132170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The entry inhibitor Myrcludex-B efficiently blocks intrahepatic virus spreading in humanized mice previously infected with hepatitis B virus.
    Volz T; Allweiss L; Ben MBarek M; Warlich M; Lohse AW; Pollok JM; Alexandrov A; Urban S; Petersen J; Lütgehetmann M; Dandri M
    J Hepatol; 2013 May; 58(5):861-7. PubMed ID: 23246506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cyclosporin A inhibits hepatitis B and hepatitis D virus entry by cyclophilin-independent interference with the NTCP receptor.
    Nkongolo S; Ni Y; Lempp FA; Kaufman C; Lindner T; Esser-Nobis K; Lohmann V; Mier W; Mehrle S; Urban S
    J Hepatol; 2014 Apr; 60(4):723-31. PubMed ID: 24295872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential of the novel antiretroviral drug rilpivirine to modulate the expression and function of drug transporters and drug-metabolising enzymes in vitro.
    Weiss J; Haefeli WE
    Int J Antimicrob Agents; 2013 May; 41(5):484-7. PubMed ID: 23428312
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vitro assessment of drug-drug interaction potential of boceprevir associated with drug metabolizing enzymes and transporters.
    Chu X; Cai X; Cui D; Tang C; Ghosal A; Chan G; Green MD; Kuo Y; Liang Y; Maciolek CM; Palamanda J; Evers R; Prueksaritanont T
    Drug Metab Dispos; 2013 Mar; 41(3):668-81. PubMed ID: 23293300
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low risk of the TMPRSS2 inhibitor camostat mesylate and its metabolite GBPA to act as perpetrators of drug-drug interactions.
    Weiss J; Bajraktari-Sylejmani G; Haefeli WE
    Chem Biol Interact; 2021 Apr; 338():109428. PubMed ID: 33647240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Telaprevir is a substrate and moderate inhibitor of P-glycoprotein, a strong inductor of ABCG2, but not an activator of PXR in vitro.
    Weiss J; Becker JP; Haefeli WE
    Int J Antimicrob Agents; 2014 Feb; 43(2):184-8. PubMed ID: 24332840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging concepts for the treatment of hepatitis delta.
    Elazar M; Glenn JS
    Curr Opin Virol; 2017 Jun; 24():55-59. PubMed ID: 28475945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Organic anion transporter 3- and organic anion transporting polypeptides 1B1- and 1B3-mediated transport of catalposide.
    Jeong HU; Kwon M; Lee Y; Yoo JS; Shin DH; Song IS; Lee HS
    Drug Des Devel Ther; 2015; 9():643-53. PubMed ID: 25653502
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatitis D Virus Entry Inhibitors Based on Repurposing Intestinal Bile Acid Reabsorption Inhibitors.
    Kirstgen M; Lowjaga KAAT; Müller SF; Goldmann N; Lehmann F; Glebe D; Baringhaus KH; Geyer J
    Viruses; 2021 Apr; 13(4):. PubMed ID: 33921515
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Virus entry and its inhibition to prevent and treat hepatitis B and hepatitis D virus infections.
    Tu T; Urban S
    Curr Opin Virol; 2018 Jun; 30():68-79. PubMed ID: 29775812
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preclinical assessment of antiviral combination therapy in a genetically humanized mouse model for hepatitis delta virus infection.
    Winer BY; Shirvani-Dastgerdi E; Bram Y; Sellau J; Low BE; Johnson H; Huang T; Hrebikova G; Heller B; Sharon Y; Giersch K; Gerges S; Seneca K; Pais MA; Frankel AS; Chiriboga L; Cullen J; Nahass RG; Lutgehetmann M; Toettcher JE; Wiles MV; Schwartz RE; Ploss A
    Sci Transl Med; 2018 Jun; 10(447):. PubMed ID: 29950446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of Transporters Involved in Beraprost Sodium Transport In Vitro.
    Oshida K; Shimamura M; Seya K; Ando A; Miyamoto Y
    Eur J Drug Metab Pharmacokinet; 2017 Feb; 42(1):117-128. PubMed ID: 26961540
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of Novel HBV/HDV Entry Inhibitors by Pharmacophore- and QSAR-Guided Virtual Screening.
    Kirstgen M; Müller SF; Lowjaga KAAT; Goldmann N; Lehmann F; Alakurtti S; Yli-Kauhaluoma J; Baringhaus KH; Krieg R; Glebe D; Geyer J
    Viruses; 2021 Jul; 13(8):. PubMed ID: 34452354
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bona fide receptor for hepatitis B and D viral infections: Mechanism, research models and molecular drug targets.
    Yu Y; Li S; Liang W
    Emerg Microbes Infect; 2018 Jul; 7(1):134. PubMed ID: 30050063
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients.
    Loglio A; Ferenci P; Uceda Renteria SC; Tham CYL; van Bömmel F; Borghi M; Holzmann H; Perbellini R; Trombetta E; Giovanelli S; Greco L; Porretti L; Prati D; Ceriotti F; Lunghi G; Bertoletti A; Lampertico P
    J Hepatol; 2019 Oct; 71(4):834-839. PubMed ID: 31302176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.